Results 291 to 300 of about 288,435 (354)

The Role of miRNAs in Chicken Immune Regulation and Prospects for Disease‐Resistant Breeding

Animal Research and One Health, EarlyView.
A schematic workflow illustrating the screening of disease‐resistant miRNAs and the generation of miRNA‐based disease‐resistant chickens via PGC‐mediated germline genome editing. ABSTRACT MicroRNAs (miRNAs) are emerging as pivotal regulators of the immune system, playing a decisive role in shaping disease resistance in chicken.
Qiangzhou Wang, Weiran Wu, Qingqing Cai, Jiaxing Wang, Qi Gao, Muhammad Iftikhar, Yulin Bi, Hao Bai, Lihong Gu, Guobin Chang, Shihao Chen   +10 more
wiley   +1 more source

Prognosis and Toxicity Stratified by Best Tumor Burden Change in Japanese Patients With Advanced Melanoma Treated With First-Line Programmed Cell Death Protein 1 Monotherapy. [PDF]

J Dermatol
Horisaki K, Yoshikawa S, Omata W, Tsutsumida A, Kiyohara Y.   +4 more
europepmc   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Variation in Immune and Inflammatory Blood Markers in Advanced Melanoma Patients Treated with PD-1 Inhibitors: A Preliminary Exploratory Study. [PDF]

Biomedicines
Bolovan LM, Panait ME, Busca A, Stanciu AE, Chiriac D, Mihalcea CE, Hotnog CM, Georgescu MT, Voinea SC, Prunoiu VM, Brasoveanu LI, Gales LN.   +11 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Optimizing biophysical properties of cellular niches to enhance stem cell‐derived extracellular vesicle function in musculoskeletal regeneration

BMEMat, EarlyView.
Extracellular vesicles (EVs) derived from stem cells show promise for applications in regenerative medicine, but their scalability and yield remain challenges. This review explores the approaches for biophysical modulations within cell niches on EV properties, discusses the current clinical application of EVs, and provides an outlook on the existing ...
Yang Xu, Chung Yin Matthew Cheung, Liling Liu, Hoi Pan Harry Cheung, Kam Yu Tam, Dai Fei Elmer Ker, Sarah H. Cartmell, Chuanbin Mao, Zhiyong Zhang, Dan Michelle Wang   +9 more
wiley   +1 more source

The Real-World Efficacy and Side Effects of Different Nivolumab Regimens in Japanese Patients with Advanced Melanoma: A Single-Center Retrospective Study. [PDF]

Cancers (Basel)
Horisaki K, Yoshikawa S, Omata W, Tsutsumida A, Kiyohara Y.   +4 more
europepmc   +1 more source

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

BMEMat, EarlyView.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen, Ying Yao, Yan Zhang, Xinyu Shi, Ling Bai, Yang Zhong, Yan Zhang, Kun Zhang   +7 more
wiley   +1 more source

BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. [PDF]

J Clin Oncol
Márquez-Rodas I, Dutriaux C, Saiag P, de la Cruz Merino L, Castañón Álvarez E, Robert C, Rodríguez-Moreno JF, Arance A, Cerezuela-Fuentes P, Montaudié H, Sanmamed MF, González-Cao M, Charles J, López Criado MP, Berrocal A, de Miguel E, Funck-Brentano E, Prey S, Álamo de la Gala MC, Melero I, Avilés-Izquierdo JA, Roman R, Garcia-Pelaez B, Rodriguez S, Trnkova ZJ, Quintero M, Maciá S, Chaney MF, Dalle S.   +28 more
europepmc   +1 more source

Harnessing nanomaterials to precisely regulate the immunosuppressive tumor microenvironment for enhanced immunotherapy

BMEMat, EarlyView.
The immunosuppressive tumor microenvironment, characterized by hypoxia, redox imbalance, elevated interstitial fluid pressure, and acidity, was comprehensively elucidated. This review discussed the etiology and consequences of the characteristics of the immunosuppressive tumor microenvironment, and analyzed the recent advancements in nanomaterials for ...
Wen Zhang, Xueyin Hu, Wei Cheng, Lumeng Zhang, Yuanfang Chen, Qinrui Fu, Luntao Liu, Saijun Fan   +7 more
wiley   +1 more source